Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity

• Published in: International journal of molecular sciences 2024-02, Vol.25 (4), p.2050
• Main Authors: MacDonald-Ramos, Karla, Monroy, Adriana, Bobadilla-Bravo, Mariana, Cerbón, Marco
• Format: Article
• Language: English
• Subjects: Bilirubin; Blood Glucose - metabolism; Body composition; Body Mass Index; C-reactive protein; Cholesterol; Cholesterol, HDL; Clinical trials; Cytokines; Development and progression; Dextrose; Diabetes; Diabetes Mellitus, Type 2 - metabolism; Diabetes therapy; Diabetics; Diet; Exercise; Female; Functional foods & nutraceuticals; Glucose; Humans; Insulin; Insulin Resistance; Kinases; Lipids; Liver cirrhosis; Liver diseases; Longitudinal Studies; Low density lipoproteins; Medical research; Medicine, Experimental; Metabolic disorders; Obesity; Obesity - drug therapy; Obesity - metabolism; Overweight; Physical fitness; prediabetes; Risk factors; silymarin; Silymarin - pharmacology; Silymarin - therapeutic use; Triglycerides; Tumor necrosis factor-TNF; Type 2 diabetes; Womens health
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25042050

Silymarin has ameliorated obesity, type 2 diabetes (T2DM), and insulin resistance (IR) in combination with standard therapy, diet, or exercise in recent studies. Obesity and IR are the main risk factors for developing T2DM and other metabolic disorders. Today, there is a need for new strategies to target IR in patients with these metabolic diseases. In the present longitudinal study, a group of non-diabetic insulin-resistant women with type 1 and type 2 obesity were given silymarin for 12 weeks, with no change in habitual diet and physical activity. We used the Homeostatic Model Assessment for Insulin Resistance Index (HOMA-IR) to determine IR at baseline and after silymarin treatment (t = 12 weeks). We obtained five timepoint oral glucose tolerance tests, and other biochemical and clinical parameters were analyzed before and after treatment. Treatment with silymarin alone significantly reduced mean fasting plasma glucose (FPG) and HOMA-IR levels at 12 weeks compared to baseline values ( < 0.05). Mean fasting plasma insulin (FPI), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg), indirect bilirubin, and C-reactive protein (CRP) levels decreased compared to baseline values, although changes were non-significant. The overall results suggest that silymarin may offer a therapeutic alternative to improve IR in non-diabetic individuals with obesity. Further clinical trials are needed in this type of patient to strengthen the results of this study.